Having grown up, lived and worked in the UK for many years, it is hard to imagine a world without Queen Elizabeth II's strong, wise and stable presence. My condolences to the Royal Family and the people of the UK and Commonwealth.

We’re pleased to share data from the ongoing Phase 1 study of ALN-HSD, an investigational #RNAi therapeutic targeting HSD17B13 in nonalcoholic steatohepatitis (NASH) patients and healthy volunteers, in collaboration with Regeneron. #RNAiTherapeutics #siRNA

Today we shared new results from the ongoing Phase 1 study of ALN-HSD, an investigational #RNAi therapeutic targeting HSD17B13 in nonalcoholic steatohepatitis (NASH) patients and healthy volunteers, in collaboration with Regeneron.

This wonderful celebration of @alnylam’s #diversity was truly inspiring. I’m so grateful to all of my colleagues for how they enthusiastically embraced this opportunity to share their cultures and learn from each other. #DiversityandInclusion #gratitude #biotech

Innovators wanted! We’ve been named Fast Company’s #1 Best Workplace for Innovators for 2022. Looking for your next challenge and a company culture that is driven by the spirit of innovation? Check out our career opportunities: bit.ly/3q03t3W. #FCBestWorkplaces #biotech

We’re pleased to welcome two leaders to Alnylam’s Management Team: Piyush Sharma as Chief Ethics & Compliance Officer and Evan Lippman as Chief Development & Strategy Officer. Both bring deep #biopharma experience & perspective instrumental to our continued growth & success.

Wonderful news that made my day! I'm incredibly proud of my @alnylam colleagues for all they do to create an inclusive and welcoming workplace for all, and of all our talented and mission-driven women colleagues who are powering the #RNAiRevolution! #BestWorkplaces #biotech

#AlnylamProud to be a Science Magazine #SCTopEmployer for 4 straight years - this time ranked #2! Rooted in our core values, our culture of innovation & inclusion, scientific excellence & commitment to our people is reflected in everything we do. Congrats to all honorees! #RNAi

Very proud of this recognition! To me, it's testament to the talent and passion of our scientists and reflects all of @alnylam's focus on maintaining the spirt of discovery and innovation that has been a hallmark of our culture since our founding 20 yrs ago. #SCTopEmployer #RNAi

Yesterday we opened our doors for #STATOpenDoors - a day of community engagement & scientific exploration in Boston/Cambridge. Thanks to all who visited our Kendall Sq HQ to learn about #RNAiTherapeutics and our programs targeting CNS diseases. STAT #RNAi #RNAiRevolution

This recognition is a testament to the strength of our company culture and the degree to which our employees are invested in our mission. THANK YOU to them for everything they do to make Alnylam Pharmaceuticals such a great place to work for all of us! #AlnylamProud #RNAiRevolution #WorkBoston

Team Alnylam and their Special Olympics MA teammates had a great time competing in the Bio-Ball finals yesterday at TD Garden! The event featured hoops, laughs, community, and a special visit from the Boston Boston Celtics' Derrick White. #bioball #SpecialOlympics #biotech

Last week, Alnylam and our SAGA (Sexuality and Gender Alliance) employee resource group hosted OUTbio's Winter Wonderland celebration. #LGBTQ #biotech professionals gathered at our Corporate HQ for an evening of networking and holiday-themed food and fun.

Celebrating 20 yrs of Alnylam. 🎉 Our 1st HQ was in a handful of offices at 790 Memorial Dr in Cambridge, MA. Today, our Global HQ in #KendallSquare anchors our #Cambridge Campus & our global office network of 22 offices in 16 countries. #Alnylam20th #RNAiRevolution #RNAi #siRNA

In 2022, we celebrated 20 yrs of Alnylam #RNAi leadership and what’s next for patients in the #RNAiRevolution. Wishing everyone happy #NewYear and to our colleagues and peers in #biopharma, sending our best wishes for a productive, prosperous and patient-focused 2023!

40yrs ago today the #OrphanDrugAct was passed fostering investment + innovation in R&D for new #RareDisease treatments. Since then #biopharma has developed >650 FDA-approved orphan drugs but our work is not finished. #ODAat40 #RNAiTherapeutics #RNAi

Patients are at the center of everything we do. The opportunity to hear about their journeys (and those who advocate for them) first-hand is always a powerful experience. That’s what made our U.S. Patient Impact Day last week so special. Guests shared their perspectives and (1/2)

With our partner Regeneron, we are pleased to share interim Phase 1 clinical data on ALN-APP, an investigational #RNAi therapeutic in development for the treatment of #alzheimersdisease and cerebral amyloid angiopathy. #RNAitherapeutics #siRNA

#Hypertension, or high blood pressure, is the leading preventable risk factor for cardiovascular disease and premature death worldwide. This World Hypertension Day learn more about the challenges people face while trying to manage their blood pressure. #WorldHypertensionDay

Today at #HeartFailure2023, we presented 18-month results from the APOLLO-B Phase 3 study of patisiran, an investigational #RNAi therapeutic in development for the treatment ATTR #amyloidosis with cardiomyopathy. #RNAiTherapeutics